Novo Nordisk launches Wegovy oral weight-loss drug in the UAE, its first market outside the US, signaling global expansion amid rising competition from Eli Lilly's Foundayo.
As UK faces surging fuel demand and a potential obesity drug revolution, the nation's economic priorities are tested.
Novo Nordisk eyes Denmark, UK, and Germany for Wegovy pill launch, targeting global weight loss market beyond US dominance.
Novo Nordisk raises 2026 outlook as Wegovy captures 65% of new US prescriptions, while Pandora faces tariff and silver price pressures.